You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 3
  • EV088/#1263  Feasibility of dose-dense neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced cervical cancer: a real-world experience in the era of the interlace trial

Article Text

Article menu
Download PDFPDF
E-Poster Viewing Abstracts
AS03. Cervical cancer
EV088/#1263  Feasibility of dose-dense neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced cervical cancer: a real-world experience in the era of the interlace trial
  1. Gabriella Schivardi1,
  2. Giuseppe Caruso1,
  3. Mariateresa Lapresa1,
  4. Gabriella Parma1,
  5. Roberta Lazzari2,
  6. Luigi De Vitis1,
  7. Elena Stefani1,
  8. Maria Teresa Achilarre1,
  9. Annalisa Garbi1,
  10. Ilaria Betella1,
  11. Giovanni Aletti1,3,
  12. Angelo Maggioni1,
  13. Vanna Zanagnolo1,
  14. Nicoletta Colombo1,4 and
  15. Francesco Multinu1
  1. 1IEO European Institute of Oncology IRCCS, Division of Gynecologic Oncology, Milano, Italy
  2. 2IEO European Institute of Oncology IRCCS, Division of Radiotherapy, Milano, Italy
  3. 3University of Milan, Department of Oncology and Hemato-oncology, Milan, Italy
  4. 4University of Milan Bicocca, Medical Gynecologic Oncology Unit, Milano, Italy

Abstract

Introduction The results of the INTERLACE trial were presented in October 2023 and demonstrated that dose-dense induction chemotherapy followed by chemoradiotherapy significantly improves oncologic outcomes in locally advanced cervical cancer. This study aimed to describe the application of this treatment scheme in a real-world setting at a referral cancer center.

Methods We included consecutive patients with cervical carcinoma who underwent dose-dense neoadjuvant chemotherapy (NACT) with carboplatin AUC2 and paclitaxel 80 mg/m2, followed by concurrent chemoradiation at the European Institute of Oncology, Milan, Italy, between July 2014 and November 2018. Clinicopathological characteristics and oncologic outcomes (disease-free survival (DFS) and overall survival (OS)) were estimated using appropriate statistics. Response to NACT was evaluated using RECIST 1.1 criteria.

Results A total of 44 patients meeting inclusion criteria were identified (table 1). All patients received a minimum of 4 cycles of NACT followed by chemoradiation. In addition, 38(86.4%) patients underwent vaginal brachytherapy. Following NACT we observed a partial/complete response in 30 (68.2%) patients, stable disease in 10 (22.7%), and progression in 4 (9.1%). Overall, 22 (50%) patients experienced a relapse or progression, while 13 (29.5%) died. The median time of follow-up for the patients who did not recur was 64.5 months (IQR 42-71). The 5-year DFS was 46.9% (95% CI 30.9-61.3), while the 5-year OS was 66.9% (95% CI 49.4-79.5) (figure 1).

Conclusion/Implications In a real-world setting, the application of the therapeutic scheme proposed in the INTERLACE trial proved to be a feasible option. All patients completed the pre-planned treatment and exhibited a high response rate to NACT.

View this table:
Abstract EV088/#1263 Table 1

Characteristics of the population included

Abstract EV088/#1263 Figure 1
Abstract EV088/#1263 Figure 1

Survival analysis of the population included (Disease-free survival, Overall survival)

https://doi.org/10.1136/ijgc-2024-IGCS.207

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.